Mutation Profiling Reveals Novel Epigenetics and Splicing Mutations in Chemorefractory Pediatric AML

Despite substantial improvement of treatment outcome in pediatric acute myeloid leukemia (AML), chemotherapy resistance remains to be a major concern. While molecular basis behind therapeutic failure was intensely interrogated, genomic alteration of chemotherapy resistance remains poorly characterized in pediatric AML. Here, we performed whole exon sequencing (WES) to identify gene mutations associated with primary and secondary chemo-resistance in pediatric AML.